Papers

1

Total Citations

37

H-Index

1

About

Donghao Xu is a leading surgical oncologist whose research focuses on advancing minimally invasive techniques for complex gastrointestinal and hepatobiliary cancers. His most impactful work centers on robotic surgery for colorectal cancer with synchronous liver metastases, a challenging clinical scenario traditionally managed with open procedures. In a landmark randomized controlled trial published in 2023, Xu demonstrated that robotic-assisted simultaneous resection is not only feasible but offers significant short-term advantages over open surgery, including reduced blood loss, faster recovery, and comparable oncologic outcomes. This study, already garnering 37 citations, has reshaped surgical decision-making for patients requiring dual-site resections. Beyond this trial, Xu’s broader contributions include optimizing perioperative protocols and investigating long-term survival outcomes in robotic colorectal surgery. His work bridges the gap between technological innovation and evidence-based practice, earning him recognition as a pioneer in robotic surgical oncology. For students and researchers, Xu’s research exemplifies how rigorous trial design can validate emerging technologies, ultimately expanding treatment options for patients with advanced cancer.

Research Focus

Key Achievements

1
H-Index
1
Papers
37
Total Citations
37
Avg Citations/Paper
🏆 Most Cited Paper
Robotic versus open surgery for simultaneous resection of rectal cancer and liver metastases: a randomized controlled trial
37 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Guangdong Testing Institute for Product Quality Supervision

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago